高级检索
当前位置: 首页 > 详情页

Surgical treatment of primary pulmonary artery sarcoma

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China [2]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Cherry Park East Street, Chaoyang District, Beijing 100029, China [3]Respiratory Department, China-Japan Friendship Hospital, Beijing, China [4]Surgical Intensive Care Unit, China-Japan Friendship Hospital, Beijing, China [5]Surgical Anesthesia Department, China-Japan Friendship Hospital, Beijing, China
出处:
ISSN:

关键词: Pulmonary artery sarcoma Pulmonary thromboendarterectomy Postoperative chemotherapy

摘要:
Objective Primary pulmonary artery sarcoma (PAS) is a rare tumor that originates from the intimal layer of the pulmonary artery or pulmonary valve and has a poor prognosis. The standard treatment for this devastating disease remains unclear. This study aimed to summarize the current standard treatments for PAS. Methods From September 2015 to January 2020, six patients were diagnosed with PAS and underwent pulmonary endarterectomy (PEA) at our department. Their medical records were retrospectively reviewed to analyze the clinical characteristics, histopathological features, and postoperative outcomes. Fourteen articles, each reporting at least 6 cases, identified 201 patients diagnosed with PAS, and 158 patients had detailed treatments and follow-up data. Results All of the patients who successfully underwent PEA were alive at follow-up, with a mean survival duration of 11.6 months (7-28 months), and one patient developed recurrence in the right upper lobe lung. Two patients received postoperative chemotherapy. In one patient, the tumor invaded the pulmonary valve. Conclusions PAS resection combined with PEA via the aid of cardiopulmonary bypass and deep hypothermic circulatory arrest could achieve maximal tumor resection in patients without metastatic lesions. An individualized surgery strategy relies on a precise preoperative imaging examination. Moreover, postoperative adjuvant therapy could yield improved survival outcomes.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 外科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 外科
JCR分区:
出版当年[2019]版:
Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Q4 SURGERY
最新[2023]版:
Q3 SURGERY Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2019版] 出版当年五年平均[2015-2019] 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China
共同第一作者:
通讯作者:
通讯机构: [1]Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China [2]Department of Cardiovascular Surgery, China-Japan Friendship Hospital, Cherry Park East Street, Chaoyang District, Beijing 100029, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)